Bristol-Myers Squibb Co (BMY)
43.30USD
17 May 2013
$0.53 (+1.24%)
$42.77
$42.99
$43.43
$42.70
11,130,086
9,889,589
$45.59
$30.64
BMY
About
Overall
| Beta: | 0.44 |
| Market Cap (Mil.): | $71,122.50 |
| Shares Outstanding (Mil.): | 1,642.55 |
| Dividend: | 0.35 |
| Yield (%): | 3.23 |
Financials
| BMY | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 49.41 | 35.66 | 35.83 |
| EPS (TTM): | 0.88 | -- | -- |
| ROI: | 6.22 | 19.36 | 18.72 |
| ROE: | 9.78 | 20.07 | 19.54 |
Bristol melanoma drug combo marks new advance in immunotherapy
CHICAGO - Melanoma patients treated with two Bristol-Myers Squibb drugs fared much better than those who received either of the medications individually, a new advance for treatments that harness the body's immune system to fight cancer.
Bristol melanoma drug combo marks new advance in immunotherapy
CHICAGO, May 15 - Melanoma patients treated with two Bristol-Myers Squibb drugs fared much better than those who received either of the medications individually, a new advance for treatments that harness the body's immune system to fight cancer.
Bristol-Myers shares jump ahead of melanoma trial data
CHICAGO/NEW YORK - Shares of drugmaker Bristol-Myers Squibb Co rose to a 10-year high on Wednesday ahead of results of an early stage trial for its new melanoma treatment, with heavy betting in the options market suggesting investors see more gains in the stock.
UPDATE 1-Bristol-Myers shares jump ahead of melanoma trial data
CHICAGO/NEW YORK, May 15 - Shares of drugmaker Bristol-Myers Squibb Co rose to a 10-year high on Wednesday ahead of results of an early stage trial for its new melanoma treatment, with heavy betting in the options market suggesting investors see more gains in the stock.
Bristol-Myers shares jump ahead of melanoma trial data
CHICAGO/NEW YORK, May 15 - Shares of drugmaker Bristol-Myers Squibb Co rose to a ten-year high on Wednesday ahead of results of an early stage trial for its new melanoma treatment, with heavy betting in the options market suggesting investors see more gains in the stock.
Bristol-Myers Squibb sales disappoint, shares fall
- Bristol-Myers Squibb reported disappointing first-quarter sales, prompting a drop in shares that have risen sharply this year on enthusiasm for its lineup of promising experimental drugs.
REFILE-UPDATE 3-Bristol-Myers Squibb sales disappoint, shares fall
April 25 - Bristol-Myers Squibb reported disappointing first-quarter sales, prompting a drop in shares that have risen sharply this year on enthusiasm for its lineup of promising experimental drugs.
Bristol profit drops sharply, but meets Wall Street forecast
- Bristol-Myers Squibb's first-quarter earnings plunged 45 percent on generic competition for its drugs, but surprisingly low taxes enabled the company to meet Wall Street's forecast.
Bristol matches profit forecast, helped by low taxes
- Bristol-Myers Squibb Co reported lower first-quarter earnings, in line with forecasts, thanks to unexpectedly lower taxes and sharply higher sales of its treatments for melanoma, leukemia and diabetes.
Bristol-Myers matches earnings forecast, helped by low taxes
- Bristol-Myers Squibb Co reported lower first-quarter earnings, in line with forecasts, thanks to unexpectedly lower taxes and sharply higher sales of its treatments for melanoma, leukemia and diabetes.
Competitors
| Price | Change | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $88.09 | +0.64 |
| Pfizer Inc. (PFE.N) | $28.96 | -0.29 |
| Merck & Co., Inc. (MRK.N) | $45.99 | -0.38 |
| Sanofi SA (SASY.PA) | €84.50 | -0.12 |
| AstraZeneca plc (AZN.L) | 3,383.00p | -6.50 |
| GlaxoSmithKline plc (GSK.L) | 1,712.50p | +5.00 |
| Eli Lilly & Co. (LLY.N) | $55.90 | -0.04 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Trading Report for (BMY). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Jefferson Research
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
